雄性激素剝奪療法市場規模、佔有率、成長分析(按 ADT 類型、適應症、給藥途徑、患者人口統計、分銷管道和地區)—產業預測,2025 年至 2032 年
市場調查報告書
商品編碼
1775653

雄性激素剝奪療法市場規模、佔有率、成長分析(按 ADT 類型、適應症、給藥途徑、患者人口統計、分銷管道和地區)—產業預測,2025 年至 2032 年

Androgen Deprivation Therapy Market Size, Share, and Growth Analysis, By Type of ADT (GnRH Analogues, Anti-androgens), By Indication, By Route of Administration, By Patient Demographics, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日期: | 出版商: SkyQuest | 英文 189 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2023 年全球雄性素剝奪療法市場規模為 67 億美元,預計將從 2024 年的 70.8 億美元成長到 2032 年的 109.4 億美元,預測期內(2025-2032 年)的複合年成長率為 5.6%。

由於前列腺癌盛行率不斷上升以及人們對荷爾蒙敏感性腫瘤認知的不斷加深,全球雄性激素剝奪療法市場正在成長。藥物傳遞方面的創新,尤其是長效注射劑和口服藥物,正在增加治療選擇。老齡化社會中診斷率的提高、優惠的報銷政策以及數位監控系統的使用,正在進一步擴大患者獲得這些治療方法的機會。然而,潛在的心臟副作用和高成本等挑戰對發展中國家構成了重大障礙。未來的主要趨勢包括整合人工智慧以最佳化治療、生物相似藥的興起以及即時荷爾蒙抑制監測的進步,所有這些都將影響長期臨床療效和市場商業化。

目錄

介紹

  • 調查目的
  • 研究範圍
  • 定義

調查方法

  • 資訊採購
  • 二次資料和一次資料方法
  • 市場規模預測
  • 市場假設與限制

執行摘要

  • 全球市場展望
  • 供需趨勢分析
  • 細分機會分析

市場動態與展望

  • 市場概覽
  • 市場規模
  • 市場動態
    • 促進因素和機會
    • 限制與挑戰
  • 波特的分析

關鍵市場考察

  • 關鍵成功因素
  • 競爭程度
  • 主要投資機會
  • 市場生態系統
  • 市場吸引力指數(2024年)
  • PESTEL分析
  • 總體經濟指標
  • 價值鏈分析
  • 定價分析
  • 案例研究
  • 顧客購買行為分析

雄性激素剝奪療法市場規模(按 ADT 類型和複合年成長率) (2025-2032)

  • 市場概覽
  • GnRH類似物
  • 抗雄激素

雄性激素剝奪療法市場規模(按適應症和複合年成長率)(2025-2032)

  • 市場概覽
  • 局部前列腺癌
  • 進行性前列腺癌

雄性激素剝奪療法市場規模(按給藥途徑和複合年成長率) (2025-2032)

  • 市場概覽
  • 肌肉注射
  • 皮下注射

雄性激素剝奪療法市場規模(按患者屬性和複合年成長率) (2025-2032)

  • 市場概覽
  • 40至60歲的男性
  • 61-75歲男性
  • 75歲或以上的男性

雄性激素剝奪療法市場規模(按分銷管道和複合年成長率) (2025-2032)

  • 市場概覽
  • 醫院
  • 癌症專科診所
  • 網路藥局
  • 零售藥局

雄性激素剝奪療法市場規模(按地區)及複合年成長率(2025-2032)

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲地區

競爭資訊

  • 前五大公司對比
  • 主要企業市場定位(2024年)
  • 主要市場參與者所採取的策略
  • 近期市場趨勢
  • 公司市場佔有率分析(2024年)
  • 主要企業簡介
    • 公司詳情
    • 產品系列分析
    • 公司分部佔有率分析
    • 收益同比對比(2022-2024 年)

主要企業簡介

  • Ferring BV
  • AstraZeneca
  • Bayer AG
  • Astellas Pharma Inc
  • Johnson & Johnson
  • Foresee Pharmaceuticals Co Ltd
  • Viatris
  • Verity Pharmaceuticals Inc
  • AbbVie Inc
  • Bristol-Myers Squibb Company
  • Tolmar Pharmaceuticals Inc

結論和建議

簡介目錄
Product Code: SQMIG35I2405

Global Androgen Deprivation Therapy Market size was valued at USD 6.7 billion in 2023 and is poised to grow from USD 7.08 billion in 2024 to USD 10.94 billion by 2032, growing at a CAGR of 5.6% during the forecast period (2025-2032).

The Global Androgen Deprivation Therapy market is experiencing growth driven by the increasing incidence of prostate cancer and heightened awareness of hormone-sensitive tumors. Innovations in drug delivery, particularly long-acting injectables and oral medications, are enhancing treatment options. Improved diagnosis rates among aging populations, favorable reimbursement policies, and the use of digital monitoring systems are further expanding patient access to these therapies. Nevertheless, challenges such as potential cardiac side effects and high costs in developing countries pose significant barriers. Key future trends include the integration of AI for optimized therapies, the rise of biosimilars, and advancements in real-time hormone suppression monitoring, all of which are poised to shape long-term clinical efficacy and market commercialization.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Androgen Deprivation Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Androgen Deprivation Therapy Market Segments Analysis

Global Androgen Deprivation Therapy Market is segmented by Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel and region. Based on Type of ADT, the market is segmented into GnRH Analogues and Anti-androgens. Based on Indication, the market is segmented into Localized Prostate Cancer and Advanced Prostate Cancer. Based on Route of Administration, the market is segmented into Intramuscular and Subcutaneous. Based on Patient Demographics, the market is segmented into Men aged 40-60, Men aged 61-75 and Men above 75. Based on Distribution Channel, the market is segmented into Hospitals, Specialized Cancer Clinics, Online Pharmacies and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Androgen Deprivation Therapy Market

The increasing global prevalence of prostate cancer among older men is significantly driving the demand for androgen deprivation therapy. This treatment remains the preferred approach for managing hormone-sensitive prostate cancer, particularly in cases of advanced or metastatic disease. Additionally, initiatives aimed at enhancing screening programs and raising awareness around early detection contribute to the growing volumes of patients seeking this therapy. As more individuals recognize the importance of timely diagnosis and intervention, the market for androgen deprivation therapy is poised for continued growth in response to these escalating needs within the healthcare landscape.

Restraints in the Global Androgen Deprivation Therapy Market

The Global Androgen Deprivation Therapy market faces significant restraints due to the high costs associated with innovative treatments, including new oral blockers and long-acting injectables. These expenses often exceed the capabilities of standard insurance and public health budgets, particularly in developing nations. This creates a major barrier to affordability, compounded by inadequate reimbursement for patients and a lack of coordination within healthcare systems. As a result, many individuals in these regions may struggle to access necessary therapies, limiting the overall growth and potential of the market. Addressing these financial and systemic challenges is essential for improving patient access to effective treatments.

Market Trends of the Global Androgen Deprivation Therapy Market

The Global Androgen Deprivation Therapy (ADT) market is witnessing a significant shift toward new-generation oral hormone blockers, driven by patient preference for convenience and reduced clinic visits. By early 2024, oral luteinizing hormone-releasing hormone (LHRH) antagonists and antiandrogens have become first-line outpatient treatment options for prostate cancer, aligning with a broader trend toward decentralized care. This transition from injectable therapies to oral administration not only enhances patient compliance but also transforms treatment paradigms, indicating a robust growth trajectory for the ADT market. As healthcare systems adapt to these innovations, the demand for oral therapies is poised to accelerate.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Case Studies
  • Customer Buying Behavior Analysis

Global Androgen Deprivation Therapy Market Size by Type of ADT & CAGR (2025-2032)

  • Market Overview
  • GnRH Analogues
  • Anti-androgens

Global Androgen Deprivation Therapy Market Size by Indication & CAGR (2025-2032)

  • Market Overview
  • Localized Prostate Cancer
  • Advanced Prostate Cancer

Global Androgen Deprivation Therapy Market Size by Route of Administration & CAGR (2025-2032)

  • Market Overview
  • Intramuscular
  • Subcutaneous

Global Androgen Deprivation Therapy Market Size by Patient Demographics & CAGR (2025-2032)

  • Market Overview
  • Men aged 40-60
  • Men aged 61-75
  • Men above 75

Global Androgen Deprivation Therapy Market Size by Distribution Channel & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Specialized Cancer Clinics
  • Online Pharmacies
  • Retail Pharmacies

Global Androgen Deprivation Therapy Market Size & CAGR (2025-2032)

  • North America (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
    • US
    • Canada
  • Europe (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Ferring B V
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Astellas Pharma Inc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Foresee Pharmaceuticals Co Ltd
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Viatris
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Verity Pharmaceuticals Inc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb Company
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Tolmar Pharmaceuticals Inc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations